🇺🇸 FDA

Intelligence · Patent portfolio

Regeneron Ireland Designated Patents

Full USPTO pharma patent portfolio for Regeneron Ireland Designated — grant dates, expiration, and drug cross-links.

Patents
8,292
Expiring ≤24m
426

Quick answer

Regeneron Ireland Designated has 8,292 pharmaceutical patents in our USPTO PatentsView index (A61K/A61P). 426 expire within 24 months — use filters for patent-cliff planning.

Page 81 of 173

  1. US 9603796

    Controlled release antimicrobial compositions and methods for the treatment of otic disorders

    Expires Mon Mar 23 2037 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  2. US 9604907

    Methods of facilitating neural cell survival using non-peptide and peptide BDNF neurotrophin mimetics

    Expires Mon Mar 23 2037 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  3. US 9598404

    Deoxycytidine kinase inhibitors

    Expires Mon Mar 16 2037 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  4. US 9596855

    Small molecule inhibitors of biofilm formation and the novel use of previously identified compounds for inhibition of biofilm formation and applications for drug therapy and medical device coating

    Expires Mon Mar 16 2037 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  5. US 9597336

    Therapy for treatment of chronic degenerative brain diseases and nervous system injury

    Expires Mon Mar 16 2037 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  6. US 9598697

    Recombinant bacterium to decrease tumor growth

    Expires Mon Mar 16 2037 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  7. US 9598694

    Micro-RNAs involved in macular degeneration

    Expires Mon Mar 16 2037 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  8. US 9598395

    Premature-termination-codons readthrough compounds

    Expires Mon Mar 16 2037 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  9. US 9597427

    Radioactive bone cement

    Expires Mon Mar 16 2037 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  10. US 9597372

    Vault complexes for cytokine delivery

    Expires Mon Mar 16 2037 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  11. US 9597290

    Particle functionalization

    Expires Mon Mar 16 2037 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  12. US 9593080

    Triazabutadienes as cleavable cross-linkers

    Expires Mon Mar 09 2037 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  13. US 9593131

    Copper-cysteamine and methods of use

    Expires Mon Mar 09 2037 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  14. US 9592309

    Positron emission tomography probe to monitor selected sugar metabolism in vivo

    Expires Mon Mar 09 2037 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  15. US 9592238

    Anti-ceramide monoclonal antibody 2A2

    Expires Mon Mar 09 2037 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  16. US 9592255

    Scaffold-free three dimensional nerve fibroblast constructs

    Expires Mon Mar 09 2037 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  17. US 9592196

    Methods and compositions for applying pharmacologic agents to the ear

    Expires Mon Mar 09 2037 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  18. US 9592256

    Compositions and methods for tissue repair with extracellular matrices

    Expires Mon Mar 09 2037 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  19. US 9593162

    Internalizing human monoclonal antibodies targeting prostate cancer cells in situ

    Expires Mon Mar 09 2037 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  20. US 9592265

    Modulation of oxidative stress, inflammation, and impaired insulin sensitivity with grape seed extract

    Expires Mon Mar 09 2037 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  21. US 9588124

    Shape tunable plasmonic nanoparticles

    Expires Mon Mar 02 2037 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  22. US 9587020

    Chimeric antigen receptor and methods of use thereof

    Expires Mon Mar 02 2037 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  23. US 9587282

    Adeno-associated virus virions with variant capsid and methods of use thereof

    Expires Mon Mar 02 2037 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  24. US 9587071

    Conjugated gold nanoparticles

    Expires Mon Mar 02 2037 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  25. US 9585558

    Hyperspectral imaging for early detection of Alzheimer'S Disease

    Expires Mon Mar 02 2037 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  26. US 9585941

    Eye drop formulation

    Expires Mon Mar 02 2037 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  27. US 9585954

    Mucosal immunization

    Expires Mon Mar 02 2037 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  28. US 9585935

    Intranasal oxytocin treatment to improve schizophrenia

    Expires Mon Mar 02 2037 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  29. US 9585936

    Method for therapeutic replenishment and enrichment of ocular surface lubrication

    Expires Mon Mar 02 2037 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  30. US 9585910

    Polymers functionalized with ion-specific recognition elements

    Expires Mon Mar 02 2037 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  31. US 9579394

    Polyanion nanocomplexes for therapeutic applications

    Expires Mon Feb 23 2037 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  32. US 9580472

    Anti-microbial peptides and methods of use thereof

    Expires Mon Feb 23 2037 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  33. US 9580718

    Attenuated live bacteria with increased acid resistance and methods of use thereof

    Expires Mon Feb 23 2037 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  34. US 9580690

    Attenuated recombinant alphaviruses incapable of replicating in mosquitoes and uses thereof

    Expires Mon Feb 23 2037 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  35. US 9580430

    9H-pyrimido[4,5-B]indoles and related analogs as BET bromodomain inhibitors

    Expires Mon Feb 23 2037 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  36. US 9579400

    Nanocarriers for drug delivery

    Expires Mon Feb 23 2037 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  37. US 9579370

    Compositions and methods for enterohemorrhagic Escherichia coli (EHEC)vaccination

    Expires Mon Feb 23 2037 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  38. US 9579346

    Treatment of macrophage-related disorders

    Expires Mon Feb 23 2037 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  39. US 9580427

    Kinase inhibitors

    Expires Mon Feb 23 2037 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  40. US 9573906

    Therapeutic compounds

    Expires Mon Feb 16 2037 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  41. US 9572828

    Treatment for melanoma

    Expires Mon Feb 16 2037 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  42. US 9572873

    Method of inducing a T lymphocyte response using T-cell immunogens derived from anti-viral proteins

    Expires Mon Feb 16 2037 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  43. US 9574191

    Selective inhibition of polyglutamine protein expression

    Expires Mon Feb 16 2037 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  44. US 9573977

    Method for preventing neoplastic transformation by inhibition of retinoblastoma protein inactivation

    Expires Mon Feb 16 2037 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  45. US 9572862

    Methods for promoting lipolysis and oxidation in liver and adipose tissue using catestatin

    Expires Mon Feb 16 2037 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  46. US 9568473

    Methods for detecting Ehrlichia infection

    Expires Mon Feb 09 2037 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  47. US 9568476

    Diagnosis and treatment of breast cancer

    Expires Mon Feb 09 2037 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  48. US 9567564

    Progenitor cells from Wharton's jelly of human umbilical cord

    Expires Mon Feb 09 2037 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

Frequently asked questions

How many patents does Regeneron Ireland Designated have?

8,292 published patents match the current filter (all indexed). The full portfolio is indexed from USPTO PatentsView (A61K/A61P).

When do Regeneron Ireland Designated patents expire?

426 patents in the full portfolio expire within 24 months. Use the expiring filters above or open individual patent pages for grant and expiration dates.

Where does this data come from?

USPTO PatentsView bulk data filtered to pharmaceutical CPC classes (A61K, A61P), cross-linked to NovaPharmaNews company and drug profiles. See our data sources page for methodology.

Data attribution: Data sources · Patent directory

Drug approvals, clinical trials, M&A, event intelligence, and company updates — weekly.

Customize topics & region
Topics
Region

No spam. Unsubscribe anytime. See our privacy policy.